Holen Sie sich die Stockscreener-App
33.62
0.09%
-0.03
Handel nachbörslich:
33.62
Immunovant Inc Aktie (IMVT) Neueste Nachrichten
Immunovant, Inc. (IMVT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Why Immunovant (IMVT) Is Down 10.3% After Halting IMVT-1402 Development in Cutaneous Lupus – And What's Next - Yahoo Finance
Sjogren’s Syndrome Market Poised for Sustained Growth Amid Advancements in Treatment and Clinical Innovation by 2036 – DelveInsight | Astellas Pharma, Immunovant Sciences, NK Cells Artiva Biotherap - Barchart.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Immunovant, Inc. (IMVT) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Immunovant (IMVT) Just Gave Investors Something To Think About - Yahoo Finance
Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull Case - Yahoo Finance
HanAll Biopharma Halts Lupus Drug Trial, Pivots to Rheumatoid Arthritis - finance.biggo.com
Bernstein Initiates Immunovant(IMVT.US) With Hold Rating, Announces Target Price $37 - Moomoo
Immunovant CLO Christopher Van Tuyl Executes Mandatory Sale of 2,846 Shares for Tax Withholding - Kalkine Media
Immunovant, Inc. Investigation Initiated: Levi & Korsinsky Investigates The Officers and Directors of Immunovant, Inc. (IMVT) - ACCESS Newswire
Immunovant, Inc. (IMVT) Securities Fraud InvestigationLevi & Korsinsky - ACCESS Newswire
IMVT Investor Alert: Levi & Korsinsky Investigates Immunovant, Inc. (IMVT) For Potential Securities Fraud - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Immunovant shares drop 6% after lupus drug stud... - Pluang
Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT) - PR Newswire
IMVT SHAREHOLDER INVESTIGATION: Levi & Korsinsky Investigates Immunovant, Inc. For Possible Securities Law Violations - ACCESS Newswire
Analysts Offer Insights on Healthcare Companies: Immunovant (IMVT) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Experimental skin lupus therapy dropped after trial misses main goal - Lupus News Today
IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down - Yahoo Finance
Lilly’s latest China drug deal; Immunovant’s setback in lupus - Yahoo Finance
Immunovant stock rating maintained at Buy by H.C. Wainwright - Investing.com Canada
Roivant reports top-line data from IMVT-1402 CLE trial - Yahoo Finance
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $53 - Moomoo
H.C. Wainwright Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $41 - Moomoo
Immunovant stock falls 6.02 percent after lupus trial miss - AD HOC NEWS
Immunovant Scraps Lupus Skin Treatment After Midstage Trial Falls Short - finance.biggo.com
Immunovant Stock Slides After Biotech Scraps Autoimmune Drug Program - Barron's
Why is Immunovant stock sliding today? By Investing.com - Investing.com Canada
Immunovant drops cutaneous lupus program after IMVT‑1402 trial miss - Mugglehead Investment Magazine
Why Is Immunovant Stock Falling Wednesday?Roivant Sciences (NASDAQ:ROIV), Immunovant (NASDAQ:IMVT) - Benzinga
Immunovant ends cutaneous lupus program after phase 2 flop - Fierce Biotech
Immunovant Pulls Plug On Lupus Program After Study Misses Primary Goal — IMVT Stock Heads For Over 3-Month Lows - Yahoo Finance
Immunovant Shares Down 6.7% Premarket After C - moomoo.com
Immunovant stock falls after lupus drug trial misses goal By Investing.com - Investing.com Canada
Roivant’s Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss - Yahoo Finance
Immunovant Shares Fall 6% After IMVT-1402 Lupus Study Misses Primary Endpoint - Yahoo Finance
Trial miss for Immunovant’s study of IMVT-1402 in CLE - The Pharma Letter
Immunovant halts lupus drug development after trial miss - Investing.com
Roivant slips on trial setback for Immunovant (ROIV:NASDAQ) - Seeking Alpha
Immunovant halts lupus drug development after trial miss By Investing.com - Investing.com Canada
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus - The Manila Times
A skin-lupus drug study missed its main goal. Its developer plans to stop testing it. - Stock Titan
Kuehn Law investigates Immunovant over potential fiduciary breaches - scanx.trade
Immunovant stock edges lower after recent clinical pipeline focus - AD HOC NEWS
Behavioral Patterns of IMVT and Institutional Flows - Stock Traders Daily
Piper Sandler Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $66 - Moomoo
Immunovant Stock Gains 12.4% in a Month: What's Driving It? - Eastern Progress
Immunovant stock holds gains as investors eye upcoming data and recent revenue growth - AD HOC NEWS
Immunovant Q1FY27 Results: $950m Moderna settlement boosts cash - scanx.trade
Immunovant Q1 2027 Earnings Call: Complete Transcript - Benzinga
Is Immunovant (IMVT) Undervalued After Its Pullback to $37.36? - Yahoo Finance
How (IMVT) Movements Inform Risk Allocation Models - Stock Traders Daily
Immunovant Announces Voting Outcomes from 2026 Annual Stockholders Meeting - Kalkine Media
Immunovant (IMVT) Slips 0.94% to $39.12 as Shares Test Resistance at $41.08OBV Breakout - vinanet.vn
Why (IMVT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
UBS Adjusts Immunovant Price Target to $40 From $24, Maintains Neutral Rating - Yahoo Finance
Immunovant (IMVT) Watch: Stays Close to Unchanged at $44.37; Technical Setup: Support at $42.15 and Resistance at $46.59 Frame the Range at the CloseBear Flag - vinanet.vn
Deep Track Capital, LP Trims Immunovant Inc (IMVT) Stake in Stra - GuruFocus
Immunovant Inc GLP-1 Receptor Agonists Weight Management Diabetes Treatments *79wfgdDXy* - Villa de la Orotava
immunovant inc glp 1 receptor agonist diabetes weight managementView IiKNF3uia - Villa de la Orotava
Immunovant (IMVT) Results at a Glance: The Available Earnings Metric Delivers a Miss under the Current Snapshot; Post-Earnings: Shares Move Lower 1.98% in the Available RecordAnalyst Consensus Shift - vinanet.vn
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm - Morningstar
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):